A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab vs Placebo in Participants With Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse
收藏DataCite Commons2026-05-04 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00013075/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to determine whether nivolmab alone or the combination of nivolumab and ipilimumab versus placebo, is safe and effective for delaying or preventing recurrence of cancer in participants who have experienced partial or entire removal of a kidney.
提供机构：
Vivli
创建时间：
2026-05-04
